靶向NRG1通路成功治疗转移性癌症提示新策略
本文报告两例标准治疗难治的晚期癌症患者(肺腺癌和胆管癌),全基因组和转录组测序分别检出SDC4-NRG1和新型ATP1B1-NRG1融合,两例均接受泛HER家族激酶抑制剂阿法替尼治疗并出现显著且持久的应答,提示NRG1融合阳性癌症无论起源部位均可能从该策略中获益。
要点
- 两例难治性晚期癌症(肺腺癌、胆管癌)均检出NRG1基因融合。
- 两例均接受阿法替尼治疗并显示显著且持久的应答。
- 胆管癌中检出新型ATP1B1-NRG1融合,此前未见报道。
核心结论
- 这些观察进一步支持使用泛HER酪氨酸激酶抑制剂治疗肺来源和肝细胞来源的NRG1融合阳性癌症。
- 作者认为更广泛地看,检出NRG1融合阳性的癌症无论起源部位均可能从这种临床方法中获益。
研究设计与样本
- 本文描述了2例对标准治疗难治的晚期癌症患者,患者1为肺腺癌,患者2为胆管癌。
- 对这两例进行了全基因组和转录组测序,部分发现经荧光原位杂交验证。
- 研究属于个性化肿瘤基因组学(POG)项目(NCT02155621)的一部分。
主要发现
- 两例肿瘤均检出NRG1基因融合阳性。
- 患者1检出SDC4-NRG1基因融合,类似融合此前已在肺癌中描述。
- 患者2检出新型ATP1B1-NRG1基因融合,胆管癌此前不是NRG1融合被描述过的疾病类型。
- 两例均接受泛HER家族激酶抑制剂阿法替尼治疗,均显示显著且持久的应答。
- 进展后对疾病部位测序,缺乏可描述疾病进展的明显基因组事件,提示广泛转录组或表观遗传机制可能与阿法替尼应答不持久有关。
关键数值与推荐
- 患者1检出SDC4-NRG1基因融合。
- 患者2检出新型ATP1B1-NRG1基因融合。
- 两例均接受泛HER家族激酶抑制剂阿法替尼治疗。
临床怎么用
- 作者认为NRG1融合阳性癌症无论起源部位均可能从泛HER酪氨酸激酶抑制剂治疗中获益。
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: NRG1 fusion-positive lung cancers have emerged as potentially actionable events in lung cancer, but clinical support is currently limited and no evidence of efficacy of this approach in cancers beyond lung has been shown. PATIENTS AND METHODS: Here, we describe two patients with advanced cancers refractory to standard therapies. Patient 1 had lung adenocarcinoma and patient 2 cholangiocarcinoma. Whole-genome and transcriptome sequencing were carried out for these cases with select findings validated by fluorescence in situ hybridization. RESULTS: Both tumors were found to be positive for NRG1 gene fusions. In patient 1, an SDC4-NRG1 gene fusion was detected, similar gene fusions having been described in lung cancers previously. In patient 2, a novel ATP1B1-NRG1 gene fusion was detected. Cholangiocarcinoma is not a disease type in which NRG1 fusions had been described previously. Integrative genome analysis was used to assess the potential functional significance of the detected genomic events including the gene fusions, prioritizing therapeutic strategies targeting the HER-family of growth factor receptors. Both patients were treated with the pan HER-family kinase inhibitor afatinib and both displayed significant and durable response to treatment. Upon progression sites of disease were sequenced. The lack of obvious genomic events to describe the disease progression indicated that broad transcriptomic or epigenetic mechanisms could be attributed to the lack of prolonged response to afatinib. CONCLUSION: These observations lend further support to the use of pan HER-tyrosine kinase inhibitors for the treatment of NRG1 fusion-positive in both cancers of lung and hepatocellular origin and indicate more broadly that cancers found to be NRG1 fusion-positive may benefit from such a clinical approach regardless of their site of origin. CLINICAL TRIAL INFORMATION: Personalized Oncogenomics (POG) Program of British Columbia: Utilization of Genomic Analysis to Better Understand Tumour Heterogeneity and Evolution (NCT02155621).
引用
- Jones MR, Lim H, Shen Y, et al. Successful targeting of the NRG1 pathway indicates novel treatment strategy for metastatic cancer. Ann Oncol. 2017. PMID: 28950338. doi:10.1093/annonc/mdx523
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。